Christopher Liu
Stock Analyst at LUCID CAPITAL MARKETS
(2.92)
# 1,670
Out of 5,006 analysts
8
Total ratings
80%
Success rate
26.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LYEL Lyell Immunopharma | Initiates: Buy | $20 | $17.85 | +12.04% | 1 | Sep 26, 2025 | |
| ADAG Adagene | Initiates: Buy | $9 | $1.99 | +352.26% | 1 | Sep 18, 2025 | |
| GNLX Genelux | Initiates: Buy | $10 | $4.54 | +120.26% | 1 | Jul 21, 2025 | |
| RLAY Relay Therapeutics | Maintains: Outperform | $19 → $18 | $5.59 | +222.00% | 1 | Dec 4, 2024 | |
| IDYA IDEAYA Biosciences | Downgrades: Market Perform | $41 → $27 | $27.49 | -1.78% | 2 | Nov 5, 2024 | |
| NUVL Nuvalent | Initiates: Market Perform | $42 | $83.85 | -49.91% | 1 | Aug 8, 2023 | |
| EXEL Exelixis | Initiates: Market Perform | $18 | $40.01 | -55.01% | 1 | Aug 8, 2023 |
Lyell Immunopharma
Sep 26, 2025
Initiates: Buy
Price Target: $20
Current: $17.85
Upside: +12.04%
Adagene
Sep 18, 2025
Initiates: Buy
Price Target: $9
Current: $1.99
Upside: +352.26%
Genelux
Jul 21, 2025
Initiates: Buy
Price Target: $10
Current: $4.54
Upside: +120.26%
Relay Therapeutics
Dec 4, 2024
Maintains: Outperform
Price Target: $19 → $18
Current: $5.59
Upside: +222.00%
IDEAYA Biosciences
Nov 5, 2024
Downgrades: Market Perform
Price Target: $41 → $27
Current: $27.49
Upside: -1.78%
Nuvalent
Aug 8, 2023
Initiates: Market Perform
Price Target: $42
Current: $83.85
Upside: -49.91%
Exelixis
Aug 8, 2023
Initiates: Market Perform
Price Target: $18
Current: $40.01
Upside: -55.01%